Averin Capital Acquisition Corp. (ACAA)

A fresh SPAC hunting in tech and health. Averin Capital Acquisition Corp., ticker ACAA, went public in February 2026 on Nasdaq, raising 250 million dollars. The company is incorporated in the United States and based in New York. Like any SPAC, it has no operating business — no revenue, no employees doing actual work, no products or services being sold. What it has is cash in a trust account and a mandate to find a business in technology or health and merge with it within roughly two years.

The structure: units split into shares and warrants. Investors bought units at ten dollars each. Each unit was one Class A share plus one-sixth of a warrant. In April 2026, about two months after the IPO, the units split. Now holders can trade Class A shares (ACAA), warrants (ACAAW), or keep the combined units (ACAAU). That separation matters if you are buying in the secondary market — you can now buy just the shares and avoid the warrant, or buy just the warrant if you are speculating on leverage.

What founders own and what that signals. Averin’s founders hold founder shares and founder warrants, which do not convert into public currency unless a deal closes. Those shares are worthless until the business combination is complete. That structure is intentional. It aligns the sponsors’ interests with public shareholders — if they fail to find a good deal, they get nothing. But it also means that when a deal does close and the stock rises, the founders’ shares and their carried interest (a cut of the upside) come into the money. Public shareholders should understand that upside is shared.

Technology and health as a thesis. Averin is targeting companies in technology and health, which is broad enough to cover software, digital health, biotech, medical devices, healthcare services, enterprise technology, consumer tech, or anything in those orbits. The size is unspecified in available filings, but most SPACs look for targets in the low-to-mid-market range — companies with 100 million to several billion dollars in enterprise value.

The SPAC clock is ticking. Averin completed its IPO in February 2026. That means it has roughly until February 2028 to announce and close a business combination. If the deadline passes without a deal, shareholders vote to liquidate the trust and get their money back (minus expenses and sponsor fees). That ticking clock is what forces SPAC management to act. It prevents a SPAC from sitting dormant indefinitely waiting for the perfect deal. But it also creates pressure to move, sometimes faster than is wise.

How the deal mechanics work. When Averin signs a target, management announces the deal to shareholders. There is a period for due diligence and negotiation. Then shareholders vote to approve the merger. If approved, the two companies merge, the target’s shareholders become owners of the public company, and the new merged entity’s shares begin trading under a new ticker. Often the merged company gets a new name too. Averin shareholders’ initial investment might be diluted if the deal requires issuing additional shares to the target company’s former owners, but they also might see appreciation if the post-merger company performs well.

The valuations game. How much of the trust goes to the target company and how much stays with public shareholders matters enormously. If Averin’s sponsors negotiate a deal that values the target cheaply relative to its cash flow or growth, public shareholders win. If they overpay, they lose. The fairness opinion (a valuation from a third party) is supposed to protect shareholders, but the opinion is only as good as the assumptions feeding it.

Risks are not subtle. Averin sponsors might fail to find a target before the deadline and the deal dissolves. They might find a target but price it poorly, leaving public shareholders underwater from day one. The target’s business might be weaker than presented in due diligence. The post-merger company might miss growth targets or face competitive pressure. And market conditions at the time of the merger might be different — what looked attractive when the SPAC launched might be less so two years later.

What public shareholders actually own right now. Until the deal closes, Averin shareholders own a claim on the trust account, which protects their initial capital, and voting rights in the shareholder meeting on the merger. The sponsor owns founder shares that are worth nothing until closing and management fees that compensate them for searching. That asymmetry is worth keeping in mind: the sponsors are betting on their ability to source and execute; you are betting on their judgment and execution, not on business fundamentals you can analyze.